The genetic-testing company Myriad Genetics' biggest up-and-coming product is a test that claims to match patients with depression to the best medications for them, based on their DNA. The test, ...
For diseases like depression, finding medications that work well for patients can be a long, arduous journey. Genetic tests now claim to speed it along by giving doctors more information about how ...
Myriad Genetics, Inc. announced that a study published in the Journal of Clinical Psychopharmacology found that the GeneSight® Psychotropic Test significantly reduced psychiatric hospitalizations in ...
The introduction of new genetic tests, like other medical innovations, can be conceptualized as a three-step process. Tests are proposed for use based on research findings and clinical reasoning; an ...
Myriad Genetics, Inc.’s MYGN GeneSight pharmacogenomics test was recently rolled out with Integrated Prescription Management (IPM), a pharmacy benefits management (PBM) company. Notably, the IPM will ...
NPR's Danielle Kutrzleben speaks with T.J. Raphael and Amber Van Moessner, the team behind the podcast Biohacked: Family Secrets, which puts a spotlight on the donor conception industry. With the ...
Dyslexia is a developmental disorder characterized by severe problems in the acquisition of reading and writing skills. It has a strong neurobiological basis. Genetic influence is estimated at 50–70%.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback